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Abstract: Small interfering RNAs (siRNAs) represent a new approach towards the inhibition of
gene expression; as such, they have rapidly emerged as promising therapeutics for a plethora of
important human pathologies including cancer, cardiovascular diseases, and other disorders of a
genetic etiology. However, the clinical translation of RNA interference (RNAi) requires safe and
efficient vectors for siRNA delivery into cells. Dendrimers are attractive nanovectors to serve this
purpose, as they present a unique, well-defined architecture and exhibit cooperative and multivalent
effects at the nanoscale. This short review presents a brief introduction to RNAi-based therapeutics,
the advantages offered by dendrimers as siRNA nanocarriers, and the remarkable results we achieved
with bio-inspired, structurally flexible covalent dendrimers. In the companion paper, we next report
our recent efforts in designing, characterizing and testing a series of self-assembled amphiphilic
dendrimers and their related structural alterations to achieve unprecedented efficient siRNA delivery
both in vitro and in vivo.
Keywords: RNAi therapeutics; siRNA delivery; covalent dendrimers; PAMAM dendrimers; nanovectors;
gene silencing
1. RNA Interference and Challenges in Small Interference RNA Therapeutics
Discovered in 1986 by the Nobel laureates Fire and Mello [1], RNA interference (RNAi)—also
known as post-transcriptional gene silencing (PTGS)—is a compendium of mechanisms involving
small RNAs that regulate the expression of genes in a variety of eukaryotic organisms. In simple
terms, the RNAi process implies the cleavage of endogenous long double-stranded RNAs into short
ribonucleic acid sequences (the so called small interfering RNAs or siRNAs, usually 21–23 bases long)
by the action of the Dicer endonuclease [2]. Upon incorporation into the multiprotein RNA-induced
silencing complex (RISC), the double helical siRNAs are unwound into two strands: The sense
(or passenger) strand is discarded, and the antisense (or guide) strand is paired to a complementary
mRNA sequence via the RISC complex. Upon binding, the targeted mRNA is in turn degraded by a
RISC subunit (known as Argonaute 2) endowed with endonuclease activity. This last step ultimately
results in the prevention of mRNA translation into the corresponding protein or, in other words,
in gene silencing. Finally, once the target mRNA degradation is accomplished, the RISC complex can
be recycled to digest other targets on the mRNA, greatly improving inhibition efficiency [3].
In the post-genomic era, siRNAs of a synthetic nature can be designed and synthesized under
good manufacturing practice (GMP) to target complementary regions on any gene of a known sequence
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to achieve its downregulation for curative purposes [4–6]. However, key to the therapeutic utility
of these RNAi triggers is the ability to introduce them into their target cells of the human body.
Indeed, naked siRNAs are not amenable to therapeutic administration. For instance, when a siRNA is
administered intravenously, it is readily digested by nucleases and largely cleared from the kidney
glomeruli before reaching the diseased organs. Moreover, the negative charge and large size of a naked
siRNA make it difficult to pass through the plasma membrane of a target cell. Even if the siRNA
molecules could reach the target tissue and be taken up by target cells, they must avoid degradation in
lysosomes via endosomal escape, a process in which the efficiency of these nucleic acid fragments is
notoriously low. As a consequence, one of the major challenges in successful RNAi therapeutics is
the discovery of safe, efficient and effective siRNA delivery vectors. Such delivery vehicles must at
least protect each siRNA from nucleases in the serum or extracellular media, enhance siRNA transport
across the cell membrane, and guide the siRNA to its proper location through interactions with the
intracellular trafficking machinery. Ideally, both viral and non-viral (nano)vectors can deliver siRNA
into cells [7], although, despite impressive transfection efficiency, the use of the former is limited
by safety concerns, including genotoxic and immunogenicity-mediated adverse events [8]. On the
contrary, non-viral delivery systems have great potential for the safer delivery of siRNA therapeutics,
although so far their performance in transfection efficiency has not reached the level requested for full
clinical exploitation [7,9–11].
2. Role of Dendrimers as siRNA Nanocarriers
In the variegated scenario of non-viral (nano)materials for siRNA delivery, dendrimers have
quickly grown as a family of synthetic nano-sized, radially symmetric molecules with fine-defined,
homogeneous and monodisperse composition endowed with enormous potential as gene therapy
nanovectors [12–14]. Structurally, dendrimers are constituted by three distinct domains (Figure 1a):
(1) A fundamental atom or, most frequently, a group of atoms defined as the core; (2) the branching
units, which, emanating from the core through diverse chemical reactions, allow the dendrimeric
molecule to grow in geometrically organized radial layers known as generations (G); and (3) an
exponentially increasing number of peripheral surface groups which constitute a multivalent nanoscale
array and can therefore form high-affinity interactions with a variety of biological targets [15].
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Figure 1. (a) Carto n representation of a dendrimer structure highlighting its three, distinct structural
motifs: The core (in light blue), the branching units forming the different G generations (in light
green), and the terminal groups (in light pink). According to a consolidate dendrimer nomenclature,
the core constitutes Generation 0 0 Therefore, the subsequent Generations G1, G2, . . . Gn refer
to the corresponding level of branching, as annotated in panel (a). (b) str ct r of the
triethanolamine (TEA)-core poly(amidoamine) dendrimers. For clarity, in panel (b), only a dendrimer
of Generation 4 (G4) is hown.
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From the synthetic viewpoint, both divergent and convergent pathways (or combinations of
thereof) can be adopted to prepare dendrimers with different generations with precisely defined,
regular structures [16,17]. To date, more than fifty families of dendrimers each with unique chemistry
and properties have been produced and are under investigation in a diversity of different biomedical
applications [18]. Among these, poly(amidoamine) (aka PAMAM) dendrimers undoubtedly constitute
the molecules most widely explored as nanocarriers for both drug and gene delivery [13,19–21].
In the specific field of nucleic acid delivery and release, this popularity can be ascribed to several
beneficial features of PAMAMs, including (i) the chemical nature of their terminal groups, which,
being primary amines, are fully protonated at the physiological pH of 7.4. This entails extremely
favorable electrostatic (Coulombic) interactions of these dendrimers with the negatively charged
nucleic acid fragments and the subsequent mutual condensation into nanoscopic particles, often called
dendriplexes; and (ii) the presence of tertiary amines within the dendritic branched structure which,
becoming protonated at lower pH values pertaining to endosomes and lysosomes, mediate the osmotic
swelling and subsequent disruption of the membranes of these vesicles, ultimately promoting the
intracellular release of the siRNA cargo. This mechanism, known as the proton-sponge hypothesis,
relies on the assumption (under debate; [22]) that the unprotonated amines of PAMAMs can absorb
protons as they are pumped into the lysosome/endosome, resulting in more protons being pumped in,
thus leading to an increased influx of Cl− ions and water. A combination of the osmotic swelling and a
swelling of the dendrimers themselves because of the repulsion between protonated amine groups
causes the rupture of the lysosomal/endosomal membranes, resulting in the subsequent release of its
contents into the cytoplasm [23].
3. Structurally Flexible PAMAM Dendrimers for Safe, Efficient and Effective siRNA Delivery
Despite the wealth of studies dating back to the early 90s yielding highly promising results
for PAMAM-based dendrimers as DNA nanovectors [24–28], only the last 10 years have witnessed
systematic investigations of this class of molecules in siRNA delivery (see Table S1 in Supplementary
Materials) [19,29–32]. In this arena, successive rounds of structure optimization led us to the design of
PAMAM dendrimers with a triethanolamine (TEA) core (Figure 1b) [33]. The rationale behind the
conception and synthesis of this new dendrimer family was that the TEA-core molecules, having the
branching units starting away from the central amine with a distance of 10 successive bonds, should
feature an extended core. As such, they were expected to be less congested in space with respect to
the prototypical NH3-core PAMAM dendrimers, in which the branches sprout directly from the small
ammonia focal point. As a consequence, the TEA-core dendrimers—with less densely packed branches
and terminal units—should be endowed with an enhanced flexibility of their arms and, as such, should
perform better as siRNA nanocarriers than their NH3-core counterparts. In essence, the hypothesis of
a greater flexibility translating into the more effective enwrapping of the nucleic acid fragment was
inspired by the behavior of histones, whose structure dynamics allows for conformational changes
related to DNA binding (required for post-translational modification) and unbinding (required to
prevent transcription) [34].
3.1. Prediction of Enhanced Flexibility and siRNA Interactions of TEA-Core Dendrimers by
Computer Simulations
The hypothesis of diverse flexibility between TEA- and NH3-core based PAMAMs was verified
by atomistic molecular dynamics (MD) simulations [35–37]. Figure 2a,b shows two MD equilibrated
structures of the G5 TEA-core and NH3-core PAMAM dendrimers at a physiological pH (7.4),
respectively. As intuitively perceived from these images, the TEA-core molecule is characterized by a
more open conformation, with a uniform void distribution within its interior, whilst its ammonia-core
counterpart is remarkably more compact, featuring a non-homogeneous, restricted void spacing. Thus,
the conformation of the TEA-core PAMAM dendrimers is such that the outer branches can freely move
and adjust to optimize binding with its siRNA cargo (Figure 2a). On the contrary, the more rigid and
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compact structure of NH3-core PAMAMs prevents these molecules from any induced-fit conformational
readjustment, and, consequently, not all of the terminal groups are available to self-orient for optimal
nucleic acid binding (Figure 2b).
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Figure 2. Equilibrated olecular dynamics conformations of G5 TEA-core (a) and NH3-core
(b) poly(amidoamine) (PAMAM) dendrimers in physiological solution (pH = 7.4, ionic strength
= 0.15 M NaCl). Each dendrimer molecule is represented as colored sticks, some ions and counterions
are visualized as purple (Na+) and green (Cl−) spheres, and water molecules are not shown for clarity.
Average radial monomer density ρ(r) for subsequent generations (from G0 to G5) of the TEA-core
(c) and the NH3-core PAMAMs (d). In all cases, the origin was set at the molecular center of mass.
Adapted from [37], published by RSC, 2013.
Quantitative substantiation was obtained from calculating the average radial monomer density
ρ(r) for e ch dendrimer type (shown in Figure 2c,d for subsequent dendrimer generations up to G5),
a quant ty defined as the number of atoms whose ce ters of mass locate within a spherical shell
of ra ius r and thickness ∆r. Accordingly, the integration of ρ(r) over r yields the total number of
dendrimer monomers as:
N(r) = 4pi
∫ R
0
r2ρ(r)dr. (1)
Focusing attention on G5 as an example, in the case of the TEA-core molecule, the whole
dendrimer ρ(r) curve (shown as a thick continuous line in Figure 2c) is characterized by the presence
of two minima—the first (more pronounced) located approximately 10 Å away from the core and the
second at ar und 17 Å—each followed by wo relat ve maxima, at about 13 and 21 Å, respectively.
These features of ρ(r) constitute a clear indication that the dendrimer cor region is denser with respect
to the middle–outer molecular portions (which are fairly hollow) and that the higher sub-generation
monomers generate a crowded layer at the dendrimer periphery. This, in turn, accounts for the
presence of a uniform distribution of hollow spaces in the central dendrimer structure, which can be
filled up by a significant number of solvent molecules, as testified by the corresponding thick dashed
line in Figure 2c. Considering the same data for the alternative G5 NH3-core dendrimer, the ρ(r) profile
for the whole molecule (thick continuous line; Figure 2d) is representative of a complete different trend:
Indeed, after the core peak, the curve quickly reaches a plateau value that spans the entire central
dendrimer region and finally increases again at the molecular periphery. In other words, all dendrimer
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sub-generations afford a substantial contribution to the whole density curve, supporting the visual
evidence (Figure 2b) of a more uniform monomer distribution within the dendrimeric structure. In line
with this observation, the corresponding water density profile (thick dashed line; Figure 2d) does not
feature any pronounced maximum in any specific region of the molecule but rather exhibits a uniform
distribution throughout the dendrimer interior.
The postulated enhanced ability of the more flexible, extended-core (TEA) PAMAMs in interacting
with siRNA molecules with respect to smaller core (NH3) dendrimers was next predicted by computer
simulations based on the so-called molecular mechanics/Poisson-Boltzmann surface area (MM/PBSA)
methodology [35–40] (see Supporting Information for detailed explanation). To this purpose, the free
energy of binding normalized by the total number of charged dendrimer terminal groups (∆Gbind/N)
between successive generations of the two different PAMAM-based molecules towards the siRNA
sequence directed against the mRNA coding for the heat shock protein 27 (Hsp27)—a small molecular
chaperone which is a vital regulator of cell survival and a major player in drug resistance—was
calculated [35]. This normalization procedure was required to compare the affinity of the different
dendrimer generations towards the double-stranded (ds) RNA fragment. As can be seen in Table 1,
∆Gbind/N is negative for all systems considered, indicating that, under in silico physiological conditions
(pH 7.4 and 0.15 M NaCl), the association of both dendrimeric nanovectors with their nucleic acid
payloads is a thermodynamically favorable and spontaneous process. However, for each dendrimer
generation, the TEA-core PAMAMs show a superior affinity for the ds-RNA sequence (i.e., ∆Gbind/N
more negative) with respect to their NH3-core counterparts. Additionally, there is a notable increase in
binding strength in passing from G4 to G5, substantially ascribable to an enhanced favorable enthalpic
component ∆Hbind/N. This aspect accounts for the general trend of better binding and, hence, better
properties as nanocarriers of high generation dendrimers, which is in agreement with experimental
evidence [32] Contextually, the entropic contribution is less unfavorable (i.e., smaller) in the case of the
TEA-core molecules. This lower value of –T∆Sbind/N can be connected again to the enhanced flexibility
and, consequently, the greater capacity of the conformational adaptation of all generations of the
enlarged-core dendrimers in enwrapping the ds-RNA molecule, followed by an enhanced productive
binding of the nucleic acid.
Table 1. In silico normalized free energy of binding (∆Gbind/N) and its major components (binding
enthalpy ∆Hbind/N and entropy variation –T∆Sbind/N) for G4–G6 TEA-core and NH3-core PAMAMs in
complex with heat shock protein 27 (Hsp27) small interfering RNA (siRNA) at pH 7.4 and 0.15 M NaCl.
The normalization factor N is the generation-specific total number of charged dendrimer terminal
groups (N). All values are expressed in kcal/mol1. Adapted from [35] with permission of John Wiley
and Sons.
TEA-Core PAMAMs NH3-Core PAMAMs
G ∆Gbind/N ∆Hbind/N −T∆Sbind/N ∆Gbind/N ∆Hbind/N −T∆Sbind/N
4 −7.57 1 −9.82 2.25 −4.57 −8.02 3.45
5 −14.9 −17.9 3.02 −11.5 −16.0 4.43
6 −17.0 −20.5 3.55 −14.1 −18.8 4.77
1 Standard deviation for all data in Table 1 is less that 1%.
The equilibrated MD snapshots of these two G5 dendrimer series in complex with the Hsp27
siRNA shown in Figure 3 offer additional insightful structural information. In fact, as can be inferred
from Figure 3a, the conformation of the TEA-core dendrimers is such that its outer branches can readily
move towards the phosphate backbone of the siRNA during complex formation so that its charged
amine groups can arrange themselves via induced-fit for optimal binding with the nucleic acid. On the
contrary, the more rigid and compact structure of the alternative PAMAM molecule prevents it from
undergoing a significant conformational readjustment required by the induced-fit (Figure 3b); as a
consequence, a smaller number of amine groups are available for optimal siRNA binding.
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Figure 3. Equilibrated molecular dynamics conformations of G5 TEA-core (a) and NH3-core (b) PAMAM
dendrimers in co plex with Hsp27 siRNA in physiological solution (pH = 7.4, ionic strength = 0.15
M NaCl). Each dendrimer molecule is represented as colored sticks, some ions and counterions
are visualized as light pink (Na+) and light green (Cl−) spheres, the siRNAs are portrayed as light
blue ribbons, and water molecules are not shown for clarity. Radial density distribution ρ(r) of the
dendrimer terminal nitrogen atoms in G5 TEA-core (c) and NH3-core (d) PAMAMs in complex with
Hsp27 siRNA (continuous lines). The corresponding distributions of the siRNA phosphorous atoms in
each siRNA/dendrimer complex are shown as dashed lines. Adapted from [35,36] with permission of
John Wiley and Sons and Bentham Science Publishers.
This differential behavior in siRNA binding is more evident when analyzing the radial density
distributions of the relevant nucleic acid/dendrimer complexes reported in Figure 3c,d. For the G5
TEA-core dendrimer/siRNA complex, the density profiles of the primary, positively charged nitrogen
atoms stretches further out towards the molecule periphery due to the electrostatic attraction of the
siRNA negatively charged phosphate moieties (Figure 3c). Contextually, the density distribution of
the phosphorous siRNA atoms reveals a good penetration of the nucleic acid fragment within the
dendrimer outer shell. Contrarily, even in complex with siRNA the NH3-core G5, PAMAM maintains a
more compact conformation that is characterized by a high degree of branch back-folding; as a result,
the density of the terminal amines on the dendrimer surface is lower, and the corresponding siRNA
phosphorous density distribution curve shows only a partial penetration of the nucleic acid within the
dendrimer molecular structure (Figure 3d).
3.2. High-Generation TEA-Core PAMAM Dendrimers as Effective In Vitro and In Vivo siRNA Nanocarriers
3.2.1. In Vitro Data
The predicted ability of TEA-core PAMAMs to generate nanoscale siRNA/dendrimer complexes
(aka dendriplexes) was experimentally verified and characterized in vitro. Figure 4a,b shows the
atomic force mic osc py (AFM) images of the Hsp27/dendrimer nanoparticles obtained using TEA-core
dendrimers from G1 to G7 [41].
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While only a few siRNA/dendrimer asse blies can be observed for smaller dendrimers (G1 and
G3), an increasing number of nanoscale particles are formed with increasing dendrimer generation
(Figure 4); in particular, starting from G4, the siRNA/dendrimer nanocomplexes progressively become
more uniform, well-defined, and compact. This suggests that G4 is the lowest threshold TEA-core
dendrimer generation for effective siRNA complexation. This assertion is substantiated by the results
of the RNA mobility assay illustrated in Figure 4c: While no gel retardation effect is observed with the
G1 dendrimer even at the maximum dendrimer-to-siRNA charge (N/P) ratio adopted (10/1), the siRNA
mobility is considerably retarded by the G4 molecule for N/P ≥ 2.5, and, for the same N/P value,
the siRNA shift in the gels is completely almost prevented by the G7 dendrimer [41]. The complexes
formed between siRNA and high generation (≥G4) TEA-core PAMAMs are completely stable in
physiological conditions, require strong ionic detergents such as Sodium Dodecyl Sulfate (SDS) to be
disrupted and, contrarily to naked siRNA, to show considerable resistance to RNase degradation [33].
The rapid and efficient cellular uptake of si / -core dendrimer nanoassembly was
demonstrated using the human castration-resist t r t t ca cer (CRPC) PC-3 cell line by confocal
fluorescence imaging. In these experi ents, i (i.e., scrambled) Hsp27 siRNA sequence
labeled with the green fluorescent dye Alexa l yed [42]. Figure 5a shows that, 4 h after
treatment, cells are populated by the gree fl i –dendrimer nanoparticles which reside
exclusively in the c ll cytoplasm (Figure 5b,c). Contextually, after cell tr atm nt with a similar amount
of Alexa 488-labelled naked siRNA, no green fluorescent nanoparticles are detected inside the cells.
The successful siRNA delivery and specific gene silencing of these flexible TEA-core PAMAMs was
next validated in the first proof-of-concept (POC) study targeting again Hsp27 PC-3 cells [42]. Prostate
cancer is the second most commonly occurring cancer in men and the fourth most commonly occurring
cancer overall; although most patients initially respond well to first-line hormone-based therapies
associated with androgen ablation, after a very short time period (≈2 years), they unfortunately
relapse [43], and no effective therapeutic regimen is available to treat this progressive condition.
Therefore, anticancer treatments based on targeting survival genes (e.g., Hsp27) using RNAi constitute
an interesting option in contrasting CRPCs [44]. The results from the POC study (Figure 6) show
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that transfecting PC-3 cells with TEA-core G7/Hsp27 siRNA complexes yields the potent, specific,
and long-lasting downregulation (>50% silencing after five days) of both targeted mRNA and
protein [42].Pharmaceutics 2019, 11, x FOR PEER REVIEW 8 of 26 
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siRNA in cell-based assays. With this high generation dendrimer, optimal gene silencing was 
achieved at an N/P value of 10, this siRNA/dendrimer charge ratio likely providing not only the best 
nucleic acid degradation protection but also the most effective siRNA deployment into the cellular 
cytoplasm by virtue of a very efficient endosomal escape mechanism. Finally, an incubation time for 
transfection of 24 h was determined as the optimal condition for G7 TEA-core PAMAM dendrimer-
mediated siRNA delivery to CRPC PC-3 cells for Hsp27 gene silencing. 
Sensitivity to serum proteins constitutes an Achilles’ heel of cationic nanovectors in siRNA 
delivery. In fact, since high N/P ratios are always required for efficient nucleic acid transfection (as 
discussed above), the resulting overall charge of the delivery complexes is positive. As such, 
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Figure 6. Quantitative analysis of (a) s 27 levels (determined by quantitative reverse
transcription polymerase chain reaction (RT-qPCR)), (b) sp27 protein expression (determined by
western blot analysis), (c) cell proliferation (determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) assay), and (d) caspase-3/7 activity (measured by a colorimetric assay)
in prostate cancer-3 (PC-3) cells three days after the TEA-core G7-mediated delivery of 50 nM
Hsp27-targeting siRNA (N/P = 10) (hot pink bars in all panels). Data for dendrimer G7 alone (blue
bars), naked Hsp27 siRNA (orange bars), and scrambled siRNA–G7 complexes (gray bars) are shown
for comparison. Values are expressed as % relative to control (non-treated cells, green bars). Adapted
from [42] with permission of John Wiley and Sons.
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Following the knockdown of Hsp27 in PC-3 cells by the G7 TEA-core PAMAM dendrimer/siRNA
complex, a remarkable anti-proliferative effect is observed (Figure 6c), in agreement with previous
results from Rocchi et al. [45], thus showing that the inhibition of Hsp27 protein expression negatively
affects PC-3 cell survival.
The main mechanism beyond this cellular effect was next demonstrated to proceed via
caspase-dependent induced apoptosis. Apoptosis is programmed cell death that involves the controlled
dismantling of intracellular components while avoiding inflammation and damage to surrounding cells.
Apoptotic caspases are a family of endoproteases that provide critical links in cell regulatory networks
controlling cell death. Specifically, the activation of these enzymes results in the inactivation/activation
of substrates, and the generation of a cascade of signaling events permitting such controlled demolition
of cellular components. As seen in Figure 6d, a three-fold increase in caspase-3/7 activity after Hsp27
siRNA/G7 TEA-core dendrimer complex treatment relative to controls is detected, ultimately confirming
that Hsp27 siRNA delivered by the G7 TEA-core dendrimer is very effective in inhibiting Hsp27
expression and thereby inducing caspase-dependent anticancer activity in human CRPC PC-3 cells.
The dependence of the TEA-core PAMAM dendrimer-mediated siRNA silencing effect on
siRNA concentration, dendrimer generation, N/P ratio and incubation time for transfection was
also investigated [42]. A clear dose-dependent gene silencing was observed using the G7 TEA-core
PAMAM nanocarrier, in line with a RNAi-mediated gene silencing mechanism. Moreover, in agreement
with the molecular simulation results (see Table 1), the gene silencing efficacy was seen to increase
with dendrimer generation, the G7 molecule being the best delivery nanovector for Hsp27 siRNA in
cell-based assays. With this high generation dendrimer, optimal gene silencing was achieved at an
N/P value of 10, this siRNA/dendrimer charge ratio likely providing not only the best nucleic acid
degradation protection but also the most effective siRNA deployment into the cellular cytoplasm by
virtue of a very efficient endosomal escape mechanism. Finally, an incubation time for transfection of
24 h was determined as the optimal condition for G7 TEA-core PAMAM dendrimer-mediated siRNA
delivery to CRPC PC-3 cells for Hsp27 gene silencing.
Sensitivity to serum proteins constitutes an Achilles’ heel of cationic nanovectors in siRNA delivery.
In fact, since high N/P ratios are always required for efficient nucleic acid transfection (as discussed
above), the resulting overall charge of the delivery complexes is positive. As such, electrostatic
forces may drive their interaction with the negatively charged serum proteins, this process eventually
resulting in the disintegration of the nanoassemblies with consequent premature nucleic acid release and
degradation. The lead G7 TEA-core PAMAM dendrimer was indeed not exempt from this drawback,
as no Hsp27 gene silencing was observed in the presence of 10% serum with G7 nanovectors loaded with
50 nM Hsp27 siRNA at the optimal, serum-free N/P ratio of 10. In trying to overcome these negative
results, gene silencing experiments were performed at progressively increasing dendrimer-to-siRNA
ratios. Potent Hsp27 gene silencing is indeed reached in PC-3 cells at N/P = 40, supported by a
strong inhibition of cell proliferation and high caspase-3/7 activation, as shown in Figure 7. Pleasingly,
the potent in vitro anticancer activity of the G7 TEA-core PAMAM-based nanovectors was paralleled
by the complete absence of toxicity, as assayed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT) tests for cell viability and by lactate dehydrogenase (LDH) release for cell membrane
damage [42]. Finally, no acute toxicity was observed in preliminary tests conducted by treating healthy
mice via a tail vein injection with scrambled siRNA–G7 complexes, naked Hsp27 siRNA, and the G7
TEA-core dendrimer alone, as well as a glucose solution as control.
In aggregate, these findings supported the concept that the flexible, high-generation TEA-core
PAMAM dendrimers could be effective nanovectors for in vitro siRNA delivery.
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3.2.2. In Vivo Data
Encouraged by the results obtained in vitro, high-generation TE -core dendrimers were tested
for in vivo gene silencing performance in various cancer models, including prostate [46], ovarian [47],
liver [48], and glioblastoma [49,50]. The application to ovarian cancer treatment represents a particularly
interesting example, since, beside the remarkable silencing of AKT—a gene activated in 36% of primary
tumors, with the activation being associated with high-grade cancer and aggressive clinical behavior,
protection to induced apoptosis, drug resistance and disease relapse [51]—the combined administration
of the anticancer drug paclitaxel with AKT siRNA delivered using G6 TEA-core PAMAM nanovectors
resulted in a synergistic therapeutic effect in vivo.
In this study, the effective AKT gene-silencing mediated by the G6 dendrimer nanocarriers
(Figure 8a,b) was first verified in SKOV-3 cells, a gold standard model for drug-resistant ovarian
cancer, as shown in Figure 8c–f. A non-specific (NS) siRNA sequence was also used in all experiments
for comparison.
As seen from Figure 8c, the G6 TEA-core PAMAM-mediated gene silencing effect is dependent on
siRNA concentration, with approximately 70% inhibition achieved using 50 nM siRNA. Interestingly,
AKT knockdown negatively affects the expression of p70S6K, an AKT effector protein involved in
cell survival within the phosphatidylinositol 3-kinase (PI3K)/AKT pathway-driven ovarian cancer
development [51]. With the same nanovector/siRNA system, the inhibition of cancer cell growth is
evident after 72 h post transfection (Figure 8e), and the loss of cell viability can be ascribed to induced
apoptosis, as monitored by the significant increase of caspase-3 activity (Figure 8f) [47].
Current chemotherapeutic regimens unfortunately have limited efficacy in patients with advanced
ovarian cancer [52]. Paclitaxel is the current first-line drug for treating this malignancy in the clinics,
and induced apoptosis has been established as one of the main mechanisms of action of this molecule.
Therefore, we speculated that, when administered together, AKT-targeting siRNA and paclitaxel might
act synergistically in promoting specific cancer cell death. This hypothesis was initially verified in
in vitro experiments, showing how the combined treatment of AKT siRNA/G6 TEA-core dendrimer
nanoparticles substantially enhanced SKOV-3 cell growth inhibition via induced apoptosis, as illustrated
in Figure 9a,b.
These promising results prompted us to proceed with in vivo experiments. Accordingly, SKOV-3
cells were subcutaneously injected in nude mice, and tumors were allowed to grow until they
reached a volume of approximately 30 mm3. The xenografts were then first treated with intratumoral
injections of either AKT siRNA/ or non-specific siRNA/G6 TEA-core dendriplexes in the absence of
paclitaxel. The differential reduction of tumor volume is well evident in the upper panel of Figure 9c:
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A tumor shrinkage of ≈50% in mice administered with the targeted siRNA with respect to those
receiving the non-specific treatment can be readily appreciated. Concomitantly, immunohistochemistry
confirmed the drastic decrease of AKT expression in the AKT knockdown mice (Figure 9d, right panel),
the corresponding tumors showing signs of necrosis (Figure 9d, left panel).
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delivery (N/P = 5). Data for non-specific (NS) siRNA–G6 complexes are shown for comparison. Protein 
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SKOV-3 cells determined 72 p.t. with G6 TEA-core PAMAM dendrimers at N/P = 5. Data for non-specific 
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As seen from Figure 8c, the G6 TEA-core PAMAM-mediated gene silencing effect is dependent 
on siRNA concentration, with approximately 70% inhibition achieved using 50 nM siRNA. 
Interestingly, AKT knockdown negatively affects the expression of p70S6K, an AKT effector protein 
involved in cell survival within the phosphatidylinositol 3-kinase (PI3K)/AKT pathway-driven ovarian 
cancer development [51]. With the same nanovector/siRNA system, the inhibition of cancer cell growth 
Figure 8. (a) Simulation of G6 TE - ri ers in complex with AKT siRNA at N/P = 5.
The dendrimers are portrayed as wine-colore s eres, ith charged amine groups depicted in pink.
siRNA molecules are shown as turquoise sticks. transparent gray field is used to represent the solvent
environment. (b) Zoomed view of one single G6 TEA-core PAMAM molecule in complex with one AKT
siRNA (colors as in panel a). Some Cl- and Na+ counterions are shown as white and light gray spheres,
respectively; water molecules are not shown for clarity. siRNA concentration-dependent inhibition of
AKT (c) and its downstream effector p706SK (d) in SKOV-3 cells three days after TEA-core G6-mediated
delivery (N/P = 5). Data for non-specific (NS) siRNA–G6 complexes are shown for comparison. Protein
expression levels were determined by western blotting, quantified by densitometry, and are expressed
as fold-change normalized to β-actin. (e) Time-dependent growth inhibition of SKOV-3 cells transfected
with G6 TEA-core PAMAM dendrimers (N/P = 5) and with non-specific (NS) siRNA–G6 complexes,
as determined by the MTT assay. Values are expressed as % relative to control (non-treated cells).
Filled bars: 24 h post transfection (p.t.), striped bars: 48 p.t., checked bars: 72 h p.t. (f) Caspase-3
activation in SKOV-3 cells determined 72 p.t. with G6 TEA-core PAMAM dendrimers at N/P = 5. Data
for non-specific (NS) siRNA–G6 complexes are shown for comparison. Values are expressed as fold
change normalized to β-actin used as control. Adapted from [47], which is an open access article
published under an ACS AuthorChoice License.
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Figure 9. SKOV-3 cell viability (a) and relative caspase-3 activation (b) after transfection with non-
specific (NS) siRNA or AKT siRNA delivered by the G6 TEA-core dendrimer nanovectors (N/P = 5) 
alone or in combination with paclitaxel (100 nM). Non-treated cells and β-actin were used as respective 
controls. (c) Tumor volumes from SKOV-3 xenografted mice treated with non-specific (NS) siRNA (top 
panel, left) or AKT siRNA delivered by the G6 TEA-core dendrimer nanovectors (N/P = 5) alone (top 
panel, right) or in combination with paclitaxel (100 nM, bottom panel). (d) Drastic reduction of AKT 
levels in tumor xenografts injected with AKT siRNA G6 TEA-core dendriplexes (bottom, left), and 
SKOV-3 cell viability ( ) and relative c pase-3 ac vation (b) after transfection with
non-specific (NS) siRNA or AKT siRNA delivered by the G6 TEA-core endrimer nanovectors (N/P
= 5) alone or in combination with paclitaxel (100 nM). Non-treated cells a d β-actin were us d as
respective controls. (c) Tumo volumes from SKOV-3 xenografted mice treated with non-specific (NS)
siRNA (top panel, left) or AKT siRNA delivered by the G6 TEA-core dendrimer nanovect rs (N/P
= 5) alone (t p panel, r ght) or in comb nation with pacli axel (100 nM, bottom panel). (d) Drastic
r duct on of AKT levels in tumor xenografts injected with KT siRNA G6 TEA-core dendriplexes
(bottom, left), and the corresponding histological sample showing sign of necrosis (bottom, right),
compared with xenografts treated with NS siRNA delivered with the same nanovectors showing no
reduction of AKT levels (top, left) and no necrosis (top, right). (e) Tumor volume during combined
treatment of AKT siRNA G6 TEA-core dendriplexes/paclitaxel (filled hot pink circles) of SKOV-3 mice
xenografts, compared with nanodelivered AKT siRNA (open hot pink circles) or paclitaxel alone (filled
gray circles). Data for nanodelivered NS siRNA are shown for control (open gray circles). Adapted
from [47], which is an open access article published under an ACS AuthorChoice License.
Finally, the same assays were performed in tandem with paclitaxel administration via mice
intraperitoneal injection. The corresponding xenografts reveal a remarkable cooperative action of
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the two treatments with respect to the chemotherapeutic drug per se (Figure 9c, lower panel), with a
reduction of tumor growth of 85% compared to the treatment with paclitaxel alone (Figure 9f) while
the G6 TEA-core dendrimer or the AKT siRNA alone have no effect (data not shown). To the best of
our knowledge, this constitutes the first study documenting a potentiated anticancer effect of paclitaxel
while co-administered with AKT siRNA mediated by dendrimer nanovectors to ovarian cancer both
in vitro and in vivo.
3.3. Low-Generation TEA-core PAMAM Dendrimers as Effective In Vitro and In Vivo siRNA Nanocarriers
Though the high-Generation G6 and G7 TEA-core dendrimers were very effective in delivering
siRNA molecules to various cancer models in vitro and in vivo, the large-scale chemical synthesis of
these molecules required for their clinical applications is laborious and very time/resource consuming
(e.g., extensive dendrimer purification is intrinsically difficult, being hampered by the presence of
highly similar side-products) [53]. These issues imply that the good manufacturing practice (GMP)
claimed for products expected to undergo clinical trials is technically very challenging. Therefore,
finding a way to endow lower generation dendrimers with effective and efficient siRNA delivery could
be a worthy goal per se, as discussed below.
3.3.1. Functional Delivery of Sticky siRNA
In 2007, Jean Paul Behr and his group showed that small interfering RNAs bearing short
complementary An/Tn (n = 5–8) sticky overhangs delivered using polyethyleneimine (PEI) result in
enhanced gene silencing with respect to standard siRNAs [54]. Since PEI is one of the best non-viral
DNA carriers but its efficiency drops dramatically during siRNA transfection [55], its ability to
quantitatively deliver sticky siRNAs could be attributed only to the presence of the complementary
An/Tn overhangs. According to Behr’s explanation, the latter can self-assemble into gene-like, long
double-stranded RNA, and this in turn allows for the successful cellular delivery by PEI by virtue
of a mechanism utterly similar to that governing plasmid DNA transfection. On the other hand, we
reasoned that an additional contributing factor to the enhanced gene silencing of nano-delivered
ssiRNAs could also be related to the inherent flexibility of the terminal, single-strand nucleic acid
fragments; this might allow them to behave as clamps that, just like protruding molecular arms, can
better enwrap and tightly hold the nanovector, thereby enhancing binding and, ultimately, delivery.
Accordingly, we set on to verify these concepts with the ultimate purpose of exploiting low generation
TEA-core PAMAM dendrimers as efficient nanocarriers in RNAi.
3.3.2. In Vitro Preliminary Data of Sticky siRNA Delivery by Lower Generation TEA-Core PAMAMs
Under this perspective, we initially constructed two sticky siRNA molecules with complementary
A5/T5 and A7/T7 3′-overhangs to target Hsp27 and TCTP (a highly conserved protein present in
all eukaryotic organisms that regulate cell survival in human tumors) in prostate and breast cancer
models [56,57]. In parallel, we also synthesized four additional non-complementary ssiRNAs (i.e., A5/A5,
A7/A7, T5/T5, and T7/T7) to investigate the effect of chemistry, length and non-complementarity on the
relevant gene silencing potential with respect to the standard (A2/T2) siRNAs discussed above [56,57].
Next, we preliminarily tested our TEA-core dendrimers from Generation 4 to Generation 7 for
their ability to deliver complementary ssiRNAs in PC-3 cells. Figure 10a shows that, contrarily to
conventional A2/T2 siRNA delivery, for which Generation 6 or (better) 7 dendrimers were requested to
achieve biological effects (see § 3.2, [42,47]), a significant gene silencing can be achieved in PC-3 cells
starting from the G5 nanocarriers, the A7/T7 ssiRNA being somewhat more effective than the A5/T5
counterpart for all nanovector generations (Figure 10a). Since G5 was the lowest and most effective
dendrimer generation for the in vitro delivery of ssiRNAs, further investigations were carried out
using this nanovector. In particular, the best, long-term gene silencing was obtained with the G5
TEA-core assisted delivery of 50 nM ssiRNas at N/P ratio = 10, as highlighted in Figure 10b.
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3.3.3. In Silico Binding Affinity of ssiRNAs with G5 TEA-Core Dendrimer Nanovectors
Before embarking in further time- and resource-consuming experimental investigations, we
performed MD simulations to predict and understand if and how the different ssiRNA overhangs
could impact G5 TEA-core mediated delivery. The in silico investigation started by verifying our own
hypothesis, according to which the protruding, flexible overhangs could promote a better interaction
and stronger binding of monomeric ssiRNAs to their dendrimeric nanocarriers via molecular dynamics
simulations. The MD results are summarized in Figure 11a (see Table A1 in Appendix A for full
MD results), while some exemplificative images extracted from the corresponding equilibrated MD
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The computer simulations reveal that both the nature of the overhangs and their length influence
the interaction of the relevant ssiRNAs with the G5 dendrimer nanocarrier. For the first aspect, the first
three columns in Table A1 show that ssiRNAs with An/An overhangs are characterized by the most
favorable free energy of binding values (∆Gbind = −409.9 kcal/mol for A5/A5 and −447.9 kcal/mol
for A7/A7), followed by the ssiRNAs bearing complementary overhangs (∆Gbind = -387.4 kcal/mol
for A5/T5 and -422.9 kcal/mol for A7/T7), and, last, by the ssiRNAs with Tn/Tn overhangs, which are
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characterized by the lowest nanovector affinity (∆Gbind = −316.8 kcal/mol for T2/T2, −344.8 kcal/mol
for T5/T5, and −402.2 kcal/mol for T7/T7, respectively). Concerning the second aspect, these data clearly
indicate that the presence of longer overhangs enhances nanovector/nucleic acid binding, the ssiRNA
with the shorted overhangs T2/T2 being the one with the lowest ∆Gbind value in the entire series.
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Further interesting data were obtained by calculating the effective free energy of binding (∆Gbind,eff),
i.e., the specific energetic contribution to ssiRNA/nanocarrier complex formation afforded only by those
dendrimer branches in constant and productive interaction with its nucleic acid cargo. An analysis of
each ssiRNA/dendrimer nanoassembly MD simulation allowed us to precisely identify and quantify
these dendrimer residues (Neff); next, a per residue decomposition of the total binding free energy
(see Supporting Information for details) led to the corresponding values of ∆Gbind,eff (Figure 11a and
Table A1). The first notable result regards Neff: Indeed, not only the smallest number of dendrimer
branches involved in nanovector binding (38) pertains to the nucleic acid fragment with the shortest
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overhangs (T2/T2), but also the values of Neff follow a clear increasing trend from Tn/Tn to An/An to
An/Tn ssiRNAs. Concomitantly, the corresponding ∆Gbind,eff values become more favorable (i.e., more
negative) in the same order.
The deconvolution of ∆Gbind,eff in its enthalpic (∆Hbind,eff) and entropic (−T∆Sbind,eff) components
(Figure 11a and Table A1) reveals that the nanovector/siRNA interaction is prevalently enthalpic in
nature, although entropic effects linked to the released of ions, counterions, and water molecules in the
bulk solvent upon complex formation also contribute in modulating the individual intermolecular
affinities. Thus, taking the ssiRNAs series bearing five-nucleotide long overhangs as an example,
it is easily seen that the A5/A5 ssiRNA has both the most favorable enthalpic contribution
(∆Hbind,eff = −592.0 kcal/mol) and the least unfavorable entropic term (−T∆Sbind,eff = 227.2 kcal/mol)
in the homologous series. The best results for the A5/A5 ssiRNA/G5 TEA core PAMAM complex can
be rationalized, from the enthalpic viewpoint, by taking into account the high number of favorable
electrostatic interactions, supported by the greatest value of Neff for this homologous series (46), along
with other non-bonded, stabilizing contacts between the nanovector and the nucleic acid, including its
overhangs (see Figure 12a). From the entropic perspective, the more rigid nature and the enhanced
clamping propensity of the A-based overhangs with respect to the T-based ones translate into more
permanent and effective contacts between the full nucleic acid fragments (overhangs included) and
the positively charged dendrimer terminal groups (Figure 12a). The least performing nanoassembly
in this series, i.e., the one involving the T5/T5 ssiRNA, is characterized by the smaller value of Neff
(41), the lowest enthalpic variation (∆Hbind,eff = −503.1 kcal/mol) and the most unfavorable entropic
component (−T∆Sbind,eff = 241.1 kcal/mol). This latter term is quickly understood, considering the
remarkable flexibility of the Tn protruding overhangs, which fluctuate in the solvent for most of the
time of the corresponding MD trajectory (Figure 12b). When interacting with the nanovector terminal
groups, these overhang molecular movements are frozen, resulting in a considerable loss of degrees
of freedom and, hence, entropic penalty. As a further effect, the corresponding ssiRNA/nanocarrier
opposite-charge contacts are suboptimal, and this directly reflects in a decrease of∆Hbind,eff. The ssiRNA
with complementary overhangs A5/T5 exhibits an intermediate behavior (−∆Hbind,eff = −554.9 kcal/mol
and −T∆Sbind,eff = 233.4 kcal/mol), stemming from a compensatory effect between the rigid An
arm (with high binding tendency) and the springy Tn arm (endowed with less efficient dendrimer
clasping propensity), as illustrated in Figure 12c. An utterly analogous situation—governed by the
same molecular factors described above—is observed for the homologous ssiRNA series bearing
longer overhangs, for which the affinity towards the G5 TEA-core dendrimer increases in the order
A7/A7 > A7/T7 > T7/T7 (Figures 11 and 12d–f, Table A1). These results allowed us to draw some
general considerations about the effect of nature and lengths of the ssiRNA overhangs on their
interaction with the G5 TEA-core dendrimer, as follows. First, longer overhangs are more beneficial to
nanovector/ssiRNA interactions than shorter ones by virtue of the higher number of dendrimer residues
(Neff) in permanent and efficient contact with the nucleic acid fragment. In addition, for a given
length of non-complementary overhangs, the more flexible nature of the Tn sequence is detrimental to
nanoassembly formation with respect to the alternative An strand, since the relevant less-optimized
nanoparticle structure and the larger entropic penalty paid upon dendrimer/ssiRNA complex formation
result in a lower affinity of the nucleic acid fragment for its nanovector.
The next part of the in silico investigation was devoted to verify the second hypothesis, according
to which ssiRNAs could self-assemble into gene-like structures via the formation of hybrid bridges
between the complementary overhang sequences and, in doing so, enhance their affinity for nanovectors.
In his original work [54], Behr already showed that this oligomerization or concatenation process
enhanced cooperative and multivalent PEI/A8/T8 ssiRNA interactions, thereby leading to better
delivery efficiency. Most importantly, however, since no concatemers were detected in the absence of
nanovectors (i.e., PEI or G5 TEA-core PAMAM dendrimers), we further reasoned that the nanocarriers
themselves must play an active role in directing encounters between individual ssiRNA/nanovector
complexes, thus promoting complementary overhang concatemerization. To assess these concepts,
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we performed further MD simulations on G5 TEA-core PAMAMs in complex with two dimeric
ssiRNAs, (A5/T5)2 and (A7/T7)2 (see Figure 13a,b). The computational results are graphically reported
in Figure 11b (and numerically listed in Table A2). When comparing these data with those relative to the
monomeric ssiRNAs (i.e., A5/T5 and A7/T7, Figure 11a and Table A1), some important information can
be immediately appreciated. First, the number of nanovector-charged branches in productive contact
with the nucleic acid are larger than twice the sum of the value predicted for the analogous monomeric
nanoassemblies (i.e., Neff = 96 for (A5/T5)2 and (2 × 44) = 88 for A5/T5, and Neff = 107 for (A7/T7)2 and
(2 × 47) = 94 for A7/T7, respectively, Table A3). This enhancement of stabilizing intermolecular contacts
for the concatenated systems can be ascribed to the presence of the extra double-stranded portion of
the hybridized ssiRNAs (Figure 13a,b), which, being more rigid and globally more negatively charged
than the single stranded overhangs, induces a further conformational adaptation of the dendrimer
terminal units to accommodate a larger number of favorable electrostatic interactions.Pharmaceutics 2019, 11, x FOR PEER REVIEW 18 of 26 
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The synergistic effect of ssiRNA concatemerization is also evident in the corresponding binding
thermodynamics. Indeed, both ∆Gbind,eff and ∆Hbind,eff for the hybridized ssiRNAs are more favorable
than two times the corresponding values for the monomeric ssiRNAs, while the decrease in the entropic
contributions (–T∆Sb nd, ff) for the dimeric ssiRNAs is less disfavoring for the former systems with
respect to twice the values for the latter ones, as summarized in Table A3.
All these data indeed provide a computational support to the idea that dimeric ssiRNAs generated
by nucleic acid fragments bearing complementary overhangs which might hybridize into a central
(An/Tn)2 double-stranded portion result in a synergistic binding with the G5 TEA-core dendrimer
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nanovector with respect to siRNAs characterized by both short and/or non-complementary overhangs.
Pleasingly, these theoretical predictions were confirmed by ethidium bromide (EB) displacement
fluorescence spectroscopy assays (Figure 13c,d), according to which the experimental binding affinity
of the different ssiRNAs for the dendrimer follows exactly the same order anticipated by simulations,
that is: An/Tn > An/An > Tn/Tn.
The final step of the in silico study concerned another fundamental aspect in nanovector-assisted
effective siRNA delivery and gene silencing—the disassembly of the nanocomplexes in the cellular
cytoplasm to make the nucleic acid cargo available to the RNAi machinery. To the purpose, advanced
computational techniques based on steered molecular dynamics (SMD) simulations were applied to the
four complexes formed by ssiRNAs bearing non-complementary overhangs, as well as by the standard
(T2/T2) siRNA and the G5 TEA-core dendrimer (see Supplementary Materials)). Briefly, during SMD
runs, each siRNA molecule was drifted away from its nanocarrier using a constant pulling speed,
and the behavior of the force require to break the corresponding complexes was recorded as a function
of time. The results from SMD simulations are shown in Figure 14a, from which it is seen that the peak
force that needs to be exerted to dissociate the nucleic acids fragments from their nanocarrier increases
in the order: 730 pN for T2/T2, 753 pN for T5/T5, 794 pN for A5/A5, 824 pN for T7/T7, and 862 pN
for A7/A7. If the nanovector/ssiRNA disassembly force is plotted against the corresponding effective
formation free energy (∆Gbinf,eff) value (Figure 11a and Table A1), a linear relationship is obtained
(Figure 14b, R2 = 0.95), indicating that the tighter the ssiRNA/dendrimer binding, the stronger the
force required to disassemble the corresponding complex. In other words, a very high affinity between
nanocarrier and cargo, although useful for protection and transport, will ultimately be detrimental to
the final step, i.e., efficient release; accordingly, the ideal system must represent the best compromise
among these counteracting effects.Pharmaceutics 2019, 11, x FOR PEER REVIEW 19 of 26 
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3.3.4. In Vitro Delivery of ssiRNAs with G5 TEA-Core Dendrimer Nanovectors
The uptake of ssiRNA/G5 TEA-core PAMAM dendriplexes by PC-3 cells was first verified
using live-cell confocal microscopy that confirmed both efficient internalization and cytoplasmic
localization of the nucleic acid-loaded nanocarriers. Since the mechanism presiding cellular uptake
of nanoparticles can involve several pathways, including macropinocytosis, clathrin-mediated
endocytosis, and caveolae-mediated endocytosis [58], the mechanism of uptake was investigated using
specific inhibitors and biomarkers of various endocytic pathways. As an example, Figure 15a shows
that a meaningful reduction of G5 TEA core dendrimer/A5/T5 ssiRNA complexes was achieved only in
the presence of the macropinocytosis inhibitor cytochalasin D, while only very weak effect was obtained
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in the presence of the two alternative inhibitors, that is genistein (an inhibitor of caveolae-mediated
endocytosis) and chlorpromazine, a clathrin-mediated uptake specific blocker. In addition, a robust
colocalization of the Alexa 647-labelled nanoparticles with dextran (a prototypic macropinocytosis
biomarker) was observed, while minor-to-moderate colocalization was evidenced using either the
transferrin of cholera toxin B (biomarkers for clathrin- and caveolae-mediated endocytosis) (Figure 15b).
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Based on all results discussed above, the ssiRNAs An/Tn, An/An, and Tn/Tn (n = 5 or 7) were
selected for further in vitro experiments. Taking again the Hsp27 as the target gene in different cancer
cell lines, the efficiency and specificity of the gene silencing effect were evaluated both at the mRNA
and protein levels [57]. Figure 16 illustrates some of the results obtained in these tests.
As seen in this figure, the G5 TEA-core dendrimer/non-sticky siRNA (A2/T2) assembly confirmed
its inability to elicit gene silencing in all cell lines, while, in agreement with computational predictions,
a substantial effect (approximately 90%) was achieved with ssiRNAs bearing complementary overhangs
(i.e., An/Tn). Moreover, again in line with in silico results, ssiRNAs ending with non-complementary
sequences can induce up to 70% gene silencing, as also seen in Figure 16. Specifically, for these
systems, as revealed by simulations, if, on the one side, a higher overhang rigidity leads to stronger
nanovector/ssiRNA interaction, on the other side, longer and more flexible overhangs are more
beneficial for the subsequent nucleic acid delivery. The results from all in silico investigations described
above unambiguously supported the conclusion that, among all ssiRNAs with non-complementary
overhangs we synthesized to empower low-generation TEA-core PAMAMs with effective delivery
capacity, those bearing A7/T7 terminals represent the best compromise in terms of both nanovector
binding and unbinding ability.
Before moving the A7/T7 ssiRNA/G5 TEA-core dendrimer complexes to in vivo tests, we further
investigated their anticancer effects resulting from Hsp27 silencing in PC-3 cells. Giving the previous
results obtained with the delivery of siRNA by the TEA-core dendrimer of Generation 6 and 7
discussed above, we expected this smaller PAMAM to be devoid of toxicity and its complexes with
the Hsp27-targeting ssiRNAs to significantly suppress cell growth via a caspase-induced apoptosis.
Indeed, as shown in Figure 17a, a notable inhibition of cell proliferation was detected after delivering
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A7/T7 ssiRNA with the G5 TEA-core nanovector with respect to non-treated cells, cells treated with the
G5 dendrimer alone, or with a scrambled (non-silencing) ssiRNA.
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Concomitantly, fluorescence-activated cell sorting (FACS) flow cytometry revealed a considerable
increase of annex V-positive apoptotic cells paralleled with the relevant activation of the apoptotic
Caspases 3 and 7. Finally, no toxicity mediated by the ssiRNA/dendrimer complexes was observed via
further MTT and lactate dehydrogenase assays, supporting the potential for in vivo experiments with
the A7/T7 ssiRNA/G5 TEA-core dendrimer nanoparticles.
3.3.5. In Vivo Delivery of ssiRNAs with G5 TEA-Core Dendrimer Nanovectors
The final part of the study concerned the evaluation of in vivo gene silencing by the in vitro most
efficient ssiRNA/nanovector system. Accordingly, a prostate cancer PC-3 xenografted mouse model
was adopted, to which the A7/T7/G5 TEA core dendrimer nanoparticles were slowly administered via
slow intratumoral injection. Treatment lasted one week, during which the mice survived well, showing
no sign of induced toxicity or weight loss. After mice sacrifice, the expression of Hsp27 in the tumors
was measured, as shown in Figure 18a,b. A significant downregulation of Hsp27 at both the mRNA
and protein levels was observed, compared to all controls, confirming that the ssiRNA delivered by
the dendrimer nanovector was able to elicit potent and specific RNAi also in vivo.
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Apoptotic caspase activation was also detected only in mice treated with the nanodelivered
ssiRNA, and immunohistochemistry images obtained with Ki-67 antibody staining finally confirmed
the remarkable inhibition of cell proliferation in the treated animals (Figure 18c,d).
4. Conclusions
In the last ten years, the number of studies involving dendrimers as safe, efficient and effective
nanovectors for drug and nucleic acid delivery have increased exponentially. This is mainly due
to the exquisite properties of these hyperbranched molecules which, by virtue of their nanoscale
size, regularly repeating structure and functional surface groups, make them an ideal drug delivery
platform. PAMAM dendrimers in particular bear primary amine groups on their periphery which,
being positively charged at physiological pH (7.4), can aptly condense negatively charged nucleic acids
for efficient gene or siRNA delivery. In addition, this class of dendrimers features tertiary amines in
their interior which become protonated at endosomal pH (5.5), thereby promoting the so-called proton
sponge effect and the subsequent release of their DNA/siRNA cargo in the cell cytoplasm.
During the same decade, our group has been particularly active in the field of design and
optimization of PAMAM-based dendrimers for siRNA delivery. In particular, we designed, synthesized,
and tested highly flexible triethanolamine-core PAMAM dendrimers which proved to be highly effective
for siRNA delivery in cancer therapeutics both in vitro and in vivo, as discussed in this brief review.
Based on its successful performance, the G5 TEA-core PAMAM dendrimer was scheduled to enter
clinical trials for siRNA-based cancer therapy in 2014; unfortunately, however, due to the unavailability
of GMP dendrimer material, the foreseen clinical trial was delayed and ultimately replaced by the use
of Smarticles® for the delivery of siRNA therapeutics [59].
Since the GPM production of dendrimer is quite a challenging process, we decided to exploit the
quintessence of nanotechnology, i.e., the controlled self-assembly of small, synthetically amenable
building blocks to generate nanosystems for siRNA delivery. Accordingly, we designed, synthesized,
and tested amphiphilic dendrons which, upon auto-organization into micelles, were able to mimic the
covalent, high generation dendrimers in size, structure and function—in particular for siRNA delivery.
These exciting self-assembled nanovectors will be the subject of the second part of this review work.
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Appendix A
Table A1. Total and effective enthalpy (∆Hbind, ∆Hbind,eff), entropy (-T∆Sbind, -T∆Sbind,eff), and free
energy of binding (∆Gbind = ∆Hbind−T∆Sbind, ∆Gbind,eff = ∆Hbind,eff−T∆Sbind,eff) for ssiRNAs featuring
complementary and non-complementary overhangs of different length with G5 TEA-core PAMAM
dendrimers. All values are in kcal/mol (standard deviation for all data in Table A1 is less that 3%).
Neff is the number of positive dendrimer charges effectively involved in ssiRNA binding. Adapted
from [57] with permission of the American Society of Chemistry.
Overhangs ∆Hbind −T∆Sbind ∆Gbind Neff ∆Hbind,eff −T∆Sbind,eff ∆Gbind,eff
T2/T2 −571.1 254.3 −316.8 38 −415.6 190.7 −224.9
T5/T5 −609.9 265.1 −344.8 41 −503.1 241.1 −262.0
A5/A5 −659.7 249.8 −409.9 46 −592.0 227.2 −364.8
A5/T5 −637.4 250.0 −387.4 44 −554.9 233.4 −321.5
T7/T7 −678.4 276.2 −402.2 45 −626.7 258.9 −367.8
A7/A7 −714.8 266.9 −447.9 52 −669.1 243.6 −425.5
A7/T7 −690.2 267.3 −422.9 47 −637.3 248.2 −389.1
Table A2. Total and effective enthalpy (∆Hbind, ∆Hbind,eff), entropy (−T∆Sbind, −T∆Sbind,eff), and free
energy of binding (∆Gbind = ∆Hbind−T∆Sbind, ∆Gbind,eff = ∆Hbind,eff−T∆Sbind,eff) for the two dimeric
ssiRNAs with G5 TEA-core PAMAM dendrimers. All values are in kcal/mol (standard deviation for all
data in Table A2 is less that 3%). Neff is the number of positive dendrimer charges effectively involve in
ssiRNA binding. Adapted from [57] with permission of the American Society of Chemistry.
Overhangs ∆Hbind −T∆Sbind ∆Gbind ∆Hbind,eff −T∆Sbind,eff ∆Gbind,eff
(A5/A5)2 −1382.7 407.3 −975.4 96 −1260.3 372.7 −887.6
(A7/T7)2 −1480.4 455.9 −1024.5 107 −1441.2 437.2 −1004.0
Table A3. Synergistic effect of the dimeric ssiRNA concatemerization on their G5 TEA-core PAMAM
dendrimer effective binding thermodynamics with respect to the corresponding monomeric ssiRNAs.
Data from Tables A1 and A2. All values are in kcal/mol.
(A5/T5)2 2 × (A5/T5) (A7/T7)2 2 × (A7/T7)
Neff 96 88 107 94
∆Hbind,eff −1260.3 −1109.8 −1441.2 −1274.6
−T∆Sbind,eff 372.7 446.8 437.2 496.4
∆Gbind,eff −887.6 −663.0 −1004.0 −778.2
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